We identified 745 DEPs up-regulated in the plasma samples from therapy-naïve CRC patients, which were mainly enriched in glycolysis/gluconeogenesis, signaling by ERBB2, MAPK activation, and extracellular matrix organization pathways. The gene discussed is ERBB2; the disease is colorectal carcinoma.